Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Acetylcysteine and Nicotine

supplement:

Acetylcysteine

Research Papers that Mention the Interaction

The effects of nicotine on pyroptotic signaling were reversed by N-acetyl-cysteine , a ROS scavenger.
Aging  •  2021  |  View Paper
Nicotine stimulated podocyte ROS generation; nonetheless, antioxidants such as N-acetyl cysteine NAC ) and TEMPOL (superoxide dismutase mimetic agent) inhibited this effect of nicotine.
PloS one  •  2016  |  View Paper
In addition, perinatal nicotine treatment significantly attenuated acetylcholine-induced arterial relaxation in offspring, which was also inhibited by NAC treatment.
Perinatal nicotine treatment resulted in a significant increase in arterial ROS production in offspring, which was abrogated by NAC.
Biology of reproduction  •  2015  |  View Paper
The antioxidant compound, N-acetyl-cysteine , abrogated nicotine-activated production of reactive oxygen species and inhibited CYP1A1 expression by nicotine.
Toxicology letters  •  2021  |  View Paper
Furthermore, the antioxidant compound N‐acetyl‐cysteine eliminated the nicotine‐activated production of reactive oxygen species (ROS) and inhibited signal transducer and activator of transcription 3 (STAT‐3) phosphorylation; these two mechanisms mediated the upregulation of IL‐6 expression by nicotine.
Journal of cellular biochemistry  •  2019  |  View Paper
Extracellular release of annexin A2 was also enhanced after H2O2 and nicotine treatments, which was suppressed by pretreatment with the antioxidant, N-acetyl cysteine.
Radiation Research  •  2016  |  View Paper
Nicotine increased the Bax/Bcl-2 ratio, which was attenuated by N-acetyl-L-cysteine , the NF-κB inhibitor, Bay 11–7082, and hexamethonium, a non-specific nAChR blocker.
PloS one  •  2016  |  View Paper
N‐acetylcysteine NAC ), a promising glutamatergic therapeutic agent, has shown some clinical efficacy in reducing nicotine use in humans and has been shown to reverse drug‐induced changes in glutamatergic neurophysiology.
Physiological reports  •  2019  |  View Paper
Nicotine exposure directly inhibited Nrf2 and increased ERK phosphorylation in cardiomyocytes, which were obstructed by NAC.
Molecular and Cellular Endocrinology  •  2019  |  View Paper
These results suggest that NAC is inefficacious in reducing nicotine relapse in females regardless of estrous cycle phase at the dose evaluated here.
Addiction biology  •  2019  |  View Paper
Show More